Adc Therapeutics SA 8-K filings

ADC Therapeutics SA has approved a new cash-based annual incentive plan to reward employees based on the company's achievement of corporate objectives.

ADC Therapeutics has entered into an agreement with Redmile Group regarding preemptive and advance subscription rights, clarifying the conditions under which Redmile's rights can be restricted.

ADC Therapeutics has amended its loan agreement, reducing the percentage of out-licensing proceeds required for debt repayment and establishing minimum sales targets for ZYNLONTA.